KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Inventory (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Change in Inventory for 17 consecutive years, with -$234.0 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory changed 0.43% to -$234.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$195.0 million through Dec 2025, down 436.21% year-over-year, with the annual reading at -$195.0 million for FY2025, 436.21% down from the prior year.
  • Change in Inventory hit -$234.0 million in Q4 2025 for Abbott Laboratories, down from -$213.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $554.0 million in Q1 2022 to a low of -$295.0 million in Q4 2023.
  • Historically, Change in Inventory has averaged $98.2 million across 5 years, with a median of $54.0 million in 2021.
  • Biggest five-year swings in Change in Inventory: skyrocketed 9420.0% in 2022 and later plummeted 256.08% in 2023.
  • Year by year, Change in Inventory stood at -$15.0 million in 2021, then soared by 1360.0% to $189.0 million in 2022, then tumbled by 256.08% to -$295.0 million in 2023, then grew by 20.34% to -$235.0 million in 2024, then grew by 0.43% to -$234.0 million in 2025.
  • Business Quant data shows Change in Inventory for ABT at -$234.0 million in Q4 2025, -$213.0 million in Q3 2025, and -$3.0 million in Q2 2025.